Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Buys 43,000 Shares of Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar purchased 43,000 shares of Anixa Biosciences stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This represents a 8.32 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Anixa Biosciences Stock Performance

Shares of NASDAQ ANIX traded up $0.15 during trading on Wednesday, reaching $2.28. The stock had a trading volume of 304,271 shares, compared to its average volume of 100,660. Anixa Biosciences, Inc. has a one year low of $2.07 and a one year high of $5.13. The stock has a market cap of $73.37 million, a PE ratio of -5.85 and a beta of 0.82. The firm's 50 day moving average price is $2.86 and its two-hundred day moving average price is $3.03.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. On average, research analysts expect that Anixa Biosciences, Inc. will post -0.42 earnings per share for the current year.

Institutional Trading of Anixa Biosciences

A number of large investors have recently modified their holdings of ANIX. Tyler Stone Wealth Management increased its holdings in shares of Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock worth $132,000 after acquiring an additional 21,008 shares during the period. International Assets Investment Management LLC increased its holdings in shares of Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock worth $1,190,000 after acquiring an additional 23,800 shares during the period. Westside Investment Management Inc. increased its holdings in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company's stock worth $110,000 after acquiring an additional 21,100 shares during the period. Concorde Asset Management LLC acquired a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $31,000. Finally, Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences in the 3rd quarter worth about $34,000. Institutional investors and hedge funds own 29.13% of the company's stock.

Wall Street Analyst Weigh In

ANIX has been the topic of several analyst reports. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital restated a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.